AXIOMATIC-SSP: Cautious Optimism on Factor XI Inhibitor in Stroke

The new factor XI inhibitor antithrombotic, milvexian, showed promising results in a dose-finding phase 2 trial in patients with acute ischemic stroke or TIA, on top of dual antiplatelet therapy.

Related Keywords

Italy ,Rome ,Lazio ,Canada ,Spain ,Barcelona ,Comunidad Autonoma De Cataluna ,Giovanna Liuzzo ,Mukul Sharma ,Mcmaster University ,Academic Research Consortium ,Catholic University Of Rome ,European Society Of Cardiology ,European Society ,Bleeding Academic Research Consortium ,Catholic University ,Stroke ,Erebrovascular Accident ,Va Cerebrovascular Accident ,Ischemic Stroke ,Thromboembolism ,Hemorrhage ,Bleeding ,Transient Ischemic Attack ,Cia ,Aspirin ,Antithrombotics ,Anti Thrombotics ,Antithrombotic Therapy ,Antithrombotic Agents ,Intracerebral Hemmorhage ,Traumatic Brain Injury ,Bi Traumatic Brain Injury ,Anticoagulation Therapy ,Anticoagulant ,Anticoagulation ,Recurrent Stroke ,Antiplatele ,